Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome

Overview of attention for article published in Frontiers in oncology, December 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (58th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

twitter: 4 X users

Citations

dimensions_citation: 1 Dimensions

Readers on

mendeley: 9 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 4 X posts from 4 X users, with an upper bound of 8,904 followers.

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome #lymphoma #lymsm https://t.co/hGBFjbiH4P

28 Dec 2021

Reply Repost Favourite

New article: Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome https://t.co/4VcdxDz4lS #TCL #lymsm #hematology https://t.co/9A2X5A0bsC

27 Dec 2021

Reply Repost Favourite

RT @gedefo_sefh: Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Bren…

09 Dec 2021

Reply Repost Favourite

Case Report: Graft Versus Tumor Effect After Non-Myeloablative Allogeneic Stem-Cell Transplantation in a Patient With Brentuximab-Vedotin Refractory Sezary Syndrome https://t.co/W05DYDxzZG

09 Dec 2021

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.